To provide a comprehensive assessment of immunotherapeutic responses fueled by CDK4/6 inhibitor and anti-PD-1 treatment, RNA-sequencing of murine tumor specimens was performed and analyzed. This evidence concerns the gene CDK4 and neoplasm.